Patent number: 6683060
Abstract: The invention discloses methods of treatment and prevention for TNF&agr;-related disorders and MMP-related disorders and compounds useful in such treatments. In particular, the invention dislcoses pharmaceutical compositions comprising a compound of the general formula:
wherein X is a Zn(II) chelating group and selected from the group consisting of (CH2)nOH, (CH2)nNH2, (CH2)nSH, (CH2)mCOOH, (CH2)mCOOR, (CH2)mCONH2, (CH2)m″CONH—OH, (CH2)m″CONH—R, and (CH2)n′O(PO3)m″(m″+1), wherein n=2, 3, 4, or 5, n′=2 or 3, m=1, 2, 3, or 4, m′=1, 2, 3, 4, 5, or 6, m″=1, 2, 3, and R=—Cm′, H2m′+1 or aryl groups, especially 1-[3,4-dihydroxy-5-(2-hydroxyethyl)-tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione, which has an inhibitory effect on matrix metalloproteinase-2 (gelatinase A) and on the binding of TNF&agr; to TNF&agr;-RI.
Type:
Grant
Filed:
February 25, 2002
Date of Patent:
January 27, 2004
Assignee:
Advanced Gene Technology Corp.
Inventors:
Li-Wei Hsu, Su-Chen Chang, Jeng-Woei Lee, Pang-Hsi Liu, Hui-Ping Lee, Yi-Ching Chen, Chun-Tsun Chen